knee osteoarthritis; chondroitin sulfate; Lequesne's algo-functional index; joint space narrowing
Abstract :
[en] Objective: To investigate the efficacy and tolerability of a 3-month duration, twice a-year, intermittent treatment with oral chondroitin sulfate (CS) in knee osteoarthritis (OA) patients. Design: A total of 120 patients with symptomatic knee OA were randomized into two groups receiving either 800 mg CS or placebo (PBO) per day for two periods of 3 months during 1 year. Primary efficacy outcome was Lequesne's algo-functional index (AFI); secondary outcome parameters included VAS, walking time, global judgment, and paracetamol consumption. Radiological progression was assessed by automatic measurement of medial femoro-tibial joint space width on weight-bearing X-rays of both knees. Clinical and biological tolerability was assessed. Results: One hundred and ten of 120 patients were included in the ITT analysis. AFI decreased significantly by 36% in the CS group after 1 year as compared to 23% in the PBO group. Similar results were found for the secondary outcomes parameters. Radiological progression at month 12 showed significantly decreased joint space width in the PBO group with no change in the CS group. Tolerability was good with only minor adverse events identically observed in both groups. Conclusion: This study provides evidences that oral CS decreased pain and improved knee function. The 3-month intermittent administration of 800 mg/day of oral CS twice a year does support the prolonged effect known with symptom-modifying agents for OA. The inhibitory effect of CS on the radiological progression of the medial femoro-tibial joint space narrowing could suggest further evidence of its structure-modifying properties in knee OA. (C) 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Disciplines :
Orthopedics, rehabilitation & sports medicine Rheumatology
Author, co-author :
Uebelhart, D.
Malaise, Michel ; Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie
Marcolongo, R.
DeVathaire, F.
Piperno, M.
Mailleux, Elisabeth ; Centre Hospitalier Universitaire de Liège - CHU > Rhumatologie
Fioravanti, A.
Matoso, L.
Vignon, E.
Language :
English
Title :
Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo
Lewis S, Crossman M, Flannelly J, Belcher C, Doherty M, Bayliss MT, et al. Chondroitin sulphation patterns in synovial fluid in osteoarthritis subsets. Ann Rheum Dis 1999;58:441-5.
Rouvinez de Rossi E, Roth M, Tajana E, Uebelhart D. Determination of chondroitin sulfates in human plasma by HPLC with UV detection of constituent OS, 4S and 6S disaccharides. Glycoconj J 1997;14:94.
Conte A, De Bernardi M, Palmieri L, Lualdi P, Mautone G, Ronca G. Metabolic fate of exogenous chondroitin sulfate in man. Arzneimittelforschung 1991;41: 768-72.
Ronca F, Palmieri L, Panicucci P, Ronca G. Antiinflammatory activity of chondroitin sulfate. Osteoarthritis Cart 1998;6(Suppl):A14-21.
Volpi N. Oral bioavailability of chondroitin sulfate (Condrosulf®) and its constituents in healthy male volunteers. Osteoarthritis Cart 2002;10:768-77.
Leeb BF, Schweitzer H, Montag K, Smolen JS. A meta analysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000;27:205-11.
McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: A systematic quality assessment and meta-analysis. JAMA 2000;283:1469-75.
Morreale P, Manopulo R, Galati M, Boccanera L, Saponati G, Bocchi L. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996;23:1385-91.
Bourgeois P, Chales G, Dehais J, Delcambre B, Kuntz JL, Rozenberg S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3×400 mg/day vs placebo. Osteoarthritis Cart 1998;6(Suppl):A25-30.
Bucsi L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cart 1998;6(Suppl): A31-6.
Mazières B, Combe B, Phan Van A, Tondut J, Grynfeltt M. Chondroitin sulfate in osteoarthritis of the knee: A prospective, double blind, placebo controlled multicenter clinical study. J Rheumatol 2001;28:173-81.
Uebelhart D, Thonar EJ, Delmas PD, Chantraine A, Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: A pilot study. Osteoarthritis Cart 1998;6(Suppl):A39-46.
Altman RD, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 1986; 29:1039-49.
Altman RD. Criteria for the classification of osteoarthritis of the knee and hip. Scand J Rheumatol 1987;65:31-9.
Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for osteoarthritis of the hip and knee. Validation-value in comparison with other assessment tests. Scand J Rheumatol 1987;0(Suppl): 6585-9.
Huskisson EC. Measurement of pain. J Rheumatol 1982;9:768-9.
Kellgren JH, Lawrence JJ. Radiologic assessment of osteoarthritis. Ann Rheum Res 1957;16:494-502.
Piperno M, Hellio le Graverand MP, Conrozier T, Bochu M, Mathieu P, Vignon E. Quantitative evaluation of joint space width in femorotibial osteoarthritis: Comparison of three radiographic views. Osteoarthritis Cart 1998;6:252-9.
Conrozier T, Tron AM, Mathieu P, Vignon E. Quantitative assessment of radiographic normal and osteoarthritic hip joint space. Osteoarthritis Cart 1995;3(Suppl):A81-7.
Vignon E, Conrozier T, Piperno M, Richard S, Carrillon Y, Fantino O. Radiographic assessment of hip and knee osteoarthritis. Recommendations: Recommended guidelines. Osteoarthritis Cart 1999;7: 434-6.
Conrozier T, Tron AM, Balblanc JC, Mathieu P, Piperno M, Fitoussi G, et al. Measurements of the hip joint space using computerized image analysis. Rev. Med (Engl edn) 1993;60(2):105-11.
Zeger S, Liang L. Longitudinal data analysis using generalized linear models. Biometrika 1986;73: 13-22.
May WL, Johnson WD. Generalized estimating equations for multivariate response with the variates having different distributions. J Biopharm Stat 1996; 6:139-53.
Alekseeva LI, Benevolenskaia LI, Nasonov EL, Chichasova NV, Kariakin AN. Structum (chondroitin sulfate) - a new agent for the treatment of osteoarthritis. Ter Arkh 1999;71:51-3.
Lequesne M. Symptomatic slow-acting drugs in osteoarthritis: a novel therapeutic concept? Rev Rhum (Engl edn) 1994;61:69-73.
Moskowitz RW. Chondroprotective agents. Do they already exist? Europ J Rheumatol Inflamm 1991; 11:121-5.
Lesquesne M, Brandt K, Bellamy N, Moskowitz R, Menkes CJ, Pelletier JP, et al. Guidelines for testing slow acting drugs in osteoarthritis. J Rheumatol 1994;21:S65-71.
Uebelhart D, Thonar EJ, Zhang J, Williams JM. Protective effect of exogenous chondroitin 4,6-sulfate in the acute degradation of articular cartilage in the rabbit. Osteoarthritis Cart 1998;6(Suppl):A6.
Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthritis Cart 1998;6(Suppl):A37-8.
Verbruggen G, Goemaere S, Veys EM. Systems to Assess the Progression of Finger Joint Osteoarthritis and the Effects of Disease Modifying Osteoarthritis Drugs. Clin Rheumatol 2002;21:231-43.
Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: A randomised, placebo-controlled clinical trial. Lancet 2001;357: 251-6.
Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati L. Glucosamine sulfate use and delay of progression of knee osteoarthritis. A 3-year, randomized, placebo-controlled, double-blind study. Arch Int Med 2002;162:2113-23.
McAlindon TE. Glucosamine for osteoarthritis: Dawn of a new era?. Lancet 2001;357:247-8.
Mazières B, Loyau G, Menkès CJ, Valat JP, Dreiser RL, Charlot J, et al. La chondroitine sulfate dans le traitement de la gonarthrose et de la coxarthrose. Rev Rhum 1992;59:466-72.
Howell DS, Altman RD. Cartilage repair and conservation in osteoarthritis. A brief review of some experimental approaches to chondroprotection. Rheum Dis Clin North Am 1993; 19:713-24.
Danao-Camara T. Potential side effects of treatment with glucosamine and chondroitin. Arthritis Rheum 2000;43:2853.
Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JW, et al. EULAR recommendations for the management of knee osteoarthritis: Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000;59:936-44.
